View More Recent Stories
-
Abbvie (ABBV) PT Raised to $209 at Piper Sandler
-
AbbVie (ABBV): EC Grants Second Indication Approval for TEPKINLY for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
-
Stifel Reiterates Buy Rating on Vigil Neuroscience Inc (VIGL)
-
Morgan Stanley has just added these three stocks to its Fresh Money Buy List
-
AbbVie (ABBV) Completes Acquisition of Cerevel Therapeutics
-
AbbVie (ABBV) Announces European Commission Approval of SKYRIZI for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
-
Abbvie (ABBV) PT Raised to $200 at Goldman Sachs
-
William Blair Reiterates Outperform Rating on Abbvie (ABBV)
-
Abbvie (ABBV) PT Raised to $210 at Truist Securities
-
Abbvie (ABBV) PT Raised to $210 at JPMorgan
-
AbbVie hikes full-year earnings guidance as Humira sales top estimates
-
AbbVie (ABBV) Misses Q2 EPS by 5c; offers guidance
-
Stocks expected to have increasing option volume: ABBV TRU HAS KDP LUV WH IBM CMG NOW LVS
-
AbbVie (ABBV) call put ratio 1 call to 1 put into quarter results
-
AbbVie (ABBV) July weekly 172.50 straddle priced into quarter results
-
Abbvie (ABBV) PT Raised to $214 at BMO Capital
-
AbbVie (ABBV) Submits Regulatory Applications to FDA and EMA for Upadacitinib in Giant Cell Arteritis
-
AbbVie (ABBV) Appoints Roopal Thakkar as and Chief Scientific Officer
-
AbbVie (ABBV) option IV flat into 2024 USA elections
-
Piper Sandler Reiterates Overweight Rating on Abbvie (ABBV)
-
AbbVie (ABBV) Appoints Robert A. Michael as CEO
-
AbbVie (ABBV) Acquires Celsius Therapeutics for $250 Million
-
AbbVie (ABBV) Introduces Alle Payment Plans
-
AbbVie (ABBV) Announces Second FDA Approval for EPKINLY
-
AbbVie (ABBV) Issues US Regulatory Update on ABBV-951
-
AbbVie (ABBV) Declares $1.55 Quarterly Dividend; 3.6% Yield
-
AbbVie (ABBV) Appoints Roxanne S. Austin to its Board
-
Abbvie (ABBV) PT Raised to $190 at Piper Sandler
-
AbbVie (ABBV) and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease
-
Top pharma stocks to own in 2024 – Citi
-
This pharma giant is 'firing on all cylinders' - Piper Sandler

